NVIDIA (NVDA) traded higher in premarket on March 18, 2026 after China approved sales of its H200 AI chips, enabling the company to restart production and resume shipments. The stock closed at $181.93 on March 17 (down 0.69%) and was quoted at $183.95 in premarket, up $2.02 or 1.11%.

AMD shares moved higher in premarket trading on March 18, 2026 after AMD and Samsung Electronics signed an MoU to broaden cooperation on AI-focused memory supply. The arrangement names Samsung as the lead HBM4 provider for AMD's Instinct MI455X and also includes DDR5 memory for sixth-gen EPYC "Venice" processors, alongside potential foundry talks.

Qualcomm said it approved a new $20 billion share repurchase program and lifted its quarterly dividend to $0.92 per share from $0.89. The actions were announced before the open on March 17, 2026, and QCOM traded higher in early Tuesday trading, up about $2.60 (+2.01%) to roughly $131.99.

ImmunityBio (NASDAQ: IBRX) climbed 6.82% in premarket trading to $8.77 on March 17, 2026 after the NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA plus BCG for certain BCG-unresponsive NMIBC patients. The change expands NCCN guidance beyond prior references centered on carcinoma in situ (CIS), while ANKTIVA’s current FDA label remains limited to CIS with or without papillary tumors following its April 2024 approval.

Uber Technologies shares moved higher in premarket trading after Nvidia outlined a robotaxi partnership that targets an initial launch in Los Angeles and San Francisco in 2027. The plan calls for a phased rollout that ultimately reaches Level 4 driverless operations and expands to 28 cities across four continents by 2028.

Meta Platforms, Inc. (META) rose 3.23% in premarket trading on March 16, 2026 to $633.01 after closing at $613.71. The move followed a Reuters report that Meta is weighing layoffs affecting 20% or more of its roughly 79,000 employees as it seeks to offset rising AI infrastructure spending, including a $600 billion data-center commitment through 2028.